Efficacy and Safety of Once-Weekly Dulaglutide in Japanese Patients with Type 2 Diabetes: The Long-Term Clinical Findings Stratified According to the Degree of Obesity

DOI
  • Murakami Masako
    Department of Diabetes and Endocrinology, Shizuoka Red Cross Hospital
  • Hara Takeshi
    Department of Clinical Laboratory, Shizuoka Red Cross Hospital
  • Imai Noboru
    Department of Clinical Laboratory, Shizuoka Red Cross Hospital Department of Neurology, Shizuoka Red Cross Hospital

Bibliographic Information

Other Title
  • 2型糖尿病における持続性GLP-1受容体作動薬デュラグルチドの有用性：肥満度別検討と長期成績

Search this article

Abstract

<p> (Purpose) The safety and efficacy of once-weekly dulaglutide (DT), were evaluated in Japanese patients with type 2 diabetes (T2DM) controlled inadequately using oral antidiabetic drugs (OADs) or insulin.</p><p> (Study design) We investigated the effect of once-weekly DT 0.75 mg over 48 weeks on glycemic control in 95 T2DM patients with inadequate glycemic control on conventional treatment. A total of 38 patients were on insulin, and 85 % of subjects were on a DPP-4 inhibitor together with metformin treatment. Concomitant OADs and insulin were not changed or uptitrated. After 48 weeks, the mean changes in the glycated hemoglobin (HbA1c) level and body mass index (BMI) were evaluated in an analysis of BMI subgroups. The incidence of adverse events was also assessed.</p><p> (Results) After 48 weeks of DT treatment, in the 95 total patients, a significant reduction in HbA1c from baseline (-1.3 %) was observed without an accompanying reduction in the BMI. The mean change from baseline in HbA1c was -1.5 % in the non-obese subgroup (<25 kg/m2) without a reduction in BMI and -1.0 % in the obese subgroup (≥25 kg/m2) with a reduction in BMI of -0.9. Gastrointestinal adverse events were relatively rare in these 95 patients.</p><p> (Conclusions) Among Japanese T2DM patients, DT administered over 48 weeks improved glycemic control in non-obese subjects without a BMI reduction as well as in obese subjects.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top